Neutralization of Lethal Potency of Tetanus Toxin using Phage Display Produced scFv Antibody
Archives of Medical Laboratory Sciences,
Vol. 7 (2021),
13 March 2021
,
Page 1-6 (e3)
https://doi.org/10.22037/amls.v7.33786
Abstract
Background and Aim: Phage display technology provides a new approach for making human antibody fragments that could be applicable in passive immune therapy. We applied the use of this technology to make human single-chain variable fragments (scFvs) specific for tetanus toxin. Tetanus toxin is a neurotoxin constituted by the association of two subunits, mediates its lethal action by blocking neuromuscular vesicle docking.
Methods: We previously found that six Human scFv clones inhibit toxin binding to ganglioside GT1b. This is the final report of human tetanus scFvs (scFv 8 and scFv 13) isolated from an immunized library of more than 106 scFv clones with in vivo neutralizing activity.
Results: Only scFv 13 can reduce the in vivo toxicity induced by tetanus toxin. Also, scFv 8 has a weak capability of reducing the in vivo toxicity of the toxin.
Conclusion: These selected ScFvs can be considered as a possible option to substitute the human tetanus immunoglobulin (HTIG) which is extensively current immunotherapy for tetanus patients. Taken together, our results suggest that the use of human tetanus scFvs may lead to a less aggressive passive immune therapy against tetanus.
*Corresponding Author: Mahdi Aminian; Email: amminian@tums.ac.ir
Please cite this article as: Khalili E, Abbasi E, Aminian M. Neutralization of Lethal Potency of Tetanus Toxin using Phage Display Produced ScFv Antibody.Arch Med Lab Sci. 2021;7:(e3). https://doi.org/10.22037/amls.v7.33786
- Tetanus
- Phage Display
- scFv
- Antibody
How to Cite
References
Gibson K, Uwineza JB, Kiviri W, Parlow J. Tetanus in developing countries: a case series and review. Canadian Journal of Anesthesia/Journal canadien d'anesthésie. 2009;56(4):307-15.
Thwaites C. Botulism and tetanus. Medicine. 2014;42(1):11-3.
Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends in biochemical sciences. 2002;27(11):552-8.
Brook I. Current concepts in the management of Clostridium tetani infection. Expert review of anti-infective therapy. 2008;6(3):327-36.
Hsu SS, Groleau G. Tetanus in the emergency department: a current review. The Journal of emergency medicine. 2001;20(4):357-65.
Ernst ME, Klepser ME, Fouts M, Marangos MN. Tetanus: pathophysiology and management. Annals of Pharmacotherapy. 1997;31(12):1507-13.
ElBakri A, Nelson PN, Odeh ROA. The state of antibody therapy. Human immunology. 2010;71(12):1243-50.
Bozzo J, Jorquera JI. Use of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role. Expert Review of Anti-infective Therapy. 2017;15(6):585-604.
Ainsworth S, Menzies S, Pleass RJ. Animal derived antibodies should be considered alongside. Wellcome Open Research .2020;5:1152020.
Newcombe C, Newcombe AR. Antibody production: polyclonal-derived biotherapeutics. Journal of Chromatography B. 2007;848(1):2-7.
da Silva FA, Corte-Real S, Goncalves J. Recombinant antibodies as therapeutic agents. BioDrugs. 2008;22(5):301-14.
Souriau C, Hudson PJ. Recombinant antibodies for cancer diagnosis and therapy. Expert opinion on biological therapy. 2003;3(2):305-18.
Reff ME, Heard C. A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Critical reviews in oncology/hematology. 2001;40(1):25-35.
Newman RA, Hanna N, Raab RW. Recombinant antibodies for human therapy. Google Patents; 1997.
Sutherland JN, Chang C, Yoder SM, Rock MT, Maynard JA. Antibodies recognizing protective pertussis toxin epitopes are preferentially elicited by natural infection versus acellular immunization. Clinical and Vaccine Immunology. 2011;18(6):954-62.
Aghebati-Maleki A, Aghebati-Maleki L. Nanobodies: emerging tools for clinical applications. International Journal of Research in Applied and Basic Medical Sciences. 2018;4(2):81-90.
Huston JS, McCartney J, Tai M-S, Mottola-hartshorn C, Jin D, Warren F, et al. Medical applications of single-chain antibodies. International reviews of immunology. 1993;10(2-3):195-217.
Manoutcharian K, Perez-Garmendia R, Gevorkian G. Recombinant antibody fragments for neurodegenerative diseases. Current neuropharmacology. 2017;15(5):779-88.
Viti F, Tarli L, Giovannoni L, Zardi L, Neri D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer research. 1999;59(2):347-52.
Wu A, Yazaki P. Designer genes: recombinant antibody fragments for biological imaging. The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2000;44(3):268.
Thie H, Meyer T, Schirrmann T, Hust M, Dubel S. Phage display derived therapeutic antibodies. Current Pharmaceutical Biotechnology. 2008;9(6):439-46.
Schirrmann T, Meyer T, Schütte M, Frenzel A, Hust M. Phage display for the generation of antibodies for proteome research, diagnostics and therapy. Molecules. 2011;16(1):412-26.
Almagro JC, Pedraza-Escalona M, Arrieta HI, Pérez-Tapia SM. Phage display libraries for antibody therapeutic discovery and development. Antibodies. 2019;8(3):44.
Khalili E, Lakzaei M, Rasaee MJ, Aminian M. Production of Recombinant Human scFv Against Tetanus Toxin Heavy Chain by Phage Display Technology. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 2015;34(5):303-9.
Binz HK, Plückthun A. Engineered proteins as specific binding reagents. Current opinion in biotechnology. 2005;16(4):459-69.
Frejd FY, Kim K-T. Affibody molecules as engineered protein drugs. Experimental & molecular medicine. 2017;49(3):e306.
Grönwall C, Ståhl S. Engineered affinity proteins—generation and applications. Journal of biotechnology. 2009;140(3-4):254-69.
Friedman M, Ståhl S. Engineered affinity proteins for tumour‐targeting applications. Biotechnology and applied biochemistry. 2009;53(1):1-29.
Brown KC. Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications. Current pharmaceutical design. 2010;16(9):1040-54.
Mullen LM, Nair SP, Ward JM, Rycroft AN, Henderson B. Phage display in the study of infectious diseases. Trends in microbiology. 2006;14(3):141-7.
Munke A, Persson J, Weiffert T, De Genst E, Meisl G, Arosio P, et al. Phage display and kinetic selection of antibodies that specifically inhibit amyloid self-replication. Proceedings of the National Academy of Sciences. 2017;114(25):6444-9.
Orner BP, Liu L, Murphy RM, Kiessling LL. Phage display affords peptides that modulate β-amyloid aggregation. Journal of the American Chemical Society. 2006;128(36):11882-9.
- Abstract Viewed: 156 times
- PDF Downloaded: 115 times